RecruitingPhase 3NCT07407803
Evaluation of TQ-B3234 Capsules in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform Neurofibromas
Studying Neurofibromatosis type 1 due to NF1 mutation or intragenic deletion
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Intervention
- TQ-B3234 capsules(drug)
- Enrollment
- 177 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2026 – 2028
Study locations (28)
- The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
- Peking Union Medical College Hospital, Beijing, Beijing Municipality, China
- Xuanwu Hospital Capital Medical University, Beijing, Beijing Municipality, China
- Beijing Tiantan Hospital, Capital Medical University, Beijing, Beijing Municipality, China
- Peking University Third Hospital, Beijing, Beijing Municipality, China
- The Southwest Hospital of Amu, Chongqing, Chongqing Municipality, China
- The First Affiliated Hospital of Fujan Medical University, Fuzhou, Fujian, China
- Gansu Provincial Cancer Hospital, Lanzhou, Gansu, China
- Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China
- Dermatology Hospital of Southern Medical University (Guangdong Provincial Dermatology Hospital / Guangdong Center for the Prevention and Control of Sexually Transmitted Diseases and Leprosy, Guangzhou, Guangdong, China
- Guangxi Medical University Cancer Hospital （ Guangxi Cancer InstituteGuangxi Cancer Hospital & Medical University Oncology School & Cancer Center）, Nanning, Guangxi, China
- Guizhou Provincial People's Hospital, Guiyang, Guizhou, China
- The second hospital of Hebei medical university, Shijiazhuang, Hebei, China
- The Second Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, China
- The First Affiliated Hospital Of Zhengzhou University, Zhengzhou, Henan, China
- +13 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07407803 on ClinicalTrials.govOther trials for Neurofibromatosis type 1 due to NF1 mutation or intragenic deletion
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07233408Tailoring an Online Platform to Promote Evidence-Based Care for Adults With Neurofibromatosis 1 and Low Health LiteracyMassachusetts General Hospital
- RECRUITINGPHASE2NCT06188741Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1University of Alabama at Birmingham
- RECRUITINGNANCT06360406Real-World Treatment Study of Koselugo (Selumetinib)AstraZeneca
- RECRUITINGPHASE1, PHASE2NCT06159166Mirdametinib Monotherapy in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF).Johns Hopkins University
- RECRUITINGPHASE1NCT06104488A Study of Avutometinib for People With Solid Tumor CancersMemorial Sloan Kettering Cancer Center
- ACTIVE NOT RECRUITINGPHASE1NCT05521048Doxycycline in Cutaneous Schwannoma (NF2)Massachusetts Eye and Ear Infirmary
- ACTIVE NOT RECRUITINGNANCT03873610Resiliency Training in Adolescents With NF1 and NF2Massachusetts General Hospital
- RECRUITINGNCT04395495RASopathy BiorepositoryChildren's Hospital Medical Center, Cincinnati
See all trials for Neurofibromatosis type 1 due to NF1 mutation or intragenic deletion →